They are targeting patients who no longer respond to current gold standard treatment, not new patients
True.
Also true is any enrollment is likely to take 6-8+ months before the first wayward patient drifts in. Even the 1st line treatments with an adjunct targeted pathway/immuno drug added in, are taking many months, to get the first patient enrolled. Despite having prior good results. The smaller 2nd line patient population enrollments are taking even longer. If PMCB ever gets approval for a Phase 1, there will be no stampede of patients into it.